The roles of stem cell memory T cells in hematological malignancies by Ling Xu et al.
REVIEW Open Access
The roles of stem cell memory T cells in
hematological malignancies
Ling Xu1,2, Yikai Zhang1,2, Gengxin Luo1 and Yangqiu Li1,2,3*
Abstract
Adoptive cell therapy (ACT) is rapidly migrating from bench to clinical therapy for hematological malignancies.
Recently, a new subtype of memory T cells, stem cell memory T (TSCM) cells, was shown to be one of the most
favorable subsets for ACT. TSCM has high self-renewal capacity and is associated with superior T cell engraftment,
persistence, and antitumor immunity. In this review, we focused on the characteristics of antigen-specific TSCM cells
and discussed their potential for immunotherapy targeting hematological malignancies.
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Introduction
T cell immunodeficiencies have been observed in patients
with hematological disorders [1]. These deficiencies lead
to the expansion of malignant clones and are thought to
play an important role in tumorigenesis [2–5]. To design
an effective approach for recovering T cell immunity, par-
ticularly antigen-specific T cell immunity, it is necessary to
accurately evaluate the T cell immune status at either the
molecular or cellular level, including characteristics such
as recent thymic output function, number of naive T cells,
diversity in the T cell receptor (TCR) repertoire, and
tumor antigen-specific cytotoxicity T cell clones [6–9].
More recently, stem cell memory T (TSCM) cells have been
described as a new immune biomarker for evaluating
long-term memory T cell immune reconstitution, which is
an important index after hematopoietic stem cell trans-
plantation (HSCT) [10–12]. TSCM cells have been shown
to be able to differentiate into central memory T cells
(TCM), effector memory (TEM), and terminal effector T
cells (TTE).
Adaptive immunity is characterized by the ability to
form long-lived immunological memory. Memory T cells
develop when antigen-specific naive CD4+ or CD8+ T cells
become activated upon antigen exposure and subse-
quently undergo proliferative expansion and differenti-
ation [13, 14]. Therefore, efficient and persistent immune
memory is essential for long-term protection against in-
fections and malignancies. Memory T cells play a critical
role in maintaining this immune defense [15]. TSCM cells
are considered as an important immune marker for the
repopulating T cell pool and immune reconstitution which
is associated with favorable clinical outcome after HSCT
[16]. TSCM cell research may support the advances in bio-
marker research, diagnosis, and therapy for hematological
malignancies [17–20]. Moreover, TSCM cell research may
be important for understanding and influencing diverse
chronic immune reactions, including graft-versus-host
disease (GVHD) [21].
TSCM cell characteristics
Memory T cells (including CD4+ and CD8+ memory T
cells) include several subtypes: stem cell memory (TSCM),
central memory (TCM), transitional memory (TTM) (de-
scribed only in CD4+ memory T cells), effector memory
(TEM), and terminal effector (TTE) T cells [16, 22]. TSCM
cells were first observed in a murine model of GVHD by
Zhang et al., who reported a new subset of post-mitotic
CD44loCD62LhiCD8+ T cells expressing Sca-1 (stem cell
antigen 1), CD122, and Bcl-2. This population of T cells
was able to generate and sustain all allogeneic T cell sub-
sets in GVHD reactions. These alloreactive CD8+ T cells
were demonstrated to have enhanced self-renewal capacity
and multipotency. These cells are capable of differentiat-
ing into TCM, TEM, and TTE cells [14, 21]. In humans, an
example came from the identification of a population of
naive yellow fever (YF)-specific CD8+ T cells after
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vaccination. These cells were stably maintained for more
than 25 years and were capable of ex vivo self-renewal. In-
depth analysis of markers and genome-wide mRNA profil-
ing have shown that these cells are distinct from genuine
naive cells from unvaccinated donors and resemble the re-
cently described stem cell-like memory subset TSCM [23].
Moreover, epigenetic analysis has also revealed that his-
tone modifications and gene expression signatures could
distinguish TSCM from other CD8
+ T cell subsets [24]. In-
creasing data have supported the notion that the human
TSCM subset is a clearly distinct subset in between the
naive T cell (TN) and TCM subsets. Human TSCM cells
have been described as a long-lived memory T cell popula-
tion which are CD45RO−, CCR7+, CD45RA+, CD62L+,
CD27+, CD28+, and IL-7Rα+. These markers are charac-
teristic of naive T cells. The immunophenotypic markers
expressed in different T cell subtypes (from TN to TTE
cells) are summarized in Table 1. TSCM cells express in-
creased levels of CD95, IL-2Rβ, CXCR3, and LFA-1 and
exhibit numerous functional attributes distinct from
memory cells. However, human TSCM cells constitute only
approximately 2–4 % of the total CD4+ and CD8+ T cell
population in the periphery and can be identified by poly-
chromatic flow cytometry based on the simultaneous ex-
pression of several naive markers together with the
memory marker CD95 [25]. A linear T cell differentiation
model and the minimum set of markers used for identify-
ing and sorting TSCM are depicted in Fig. 1 [25].
Self-renewing memory T cells may be regulated by
shared signaling pathways such as those involved in
hematopoietic stem cells or memory B cells. The Wnt-
β-catenin pathway is an evolutionarily conserved path-
way that regulates hematopoietic stem cell self-renewal
and multipotency by limiting stem cell proliferation and
differentiation. Similarly, a key role for Wnt signaling
during the maintenance of “stemness” in CD8+ TSCM
cells was demonstrated by Gattinoni et al. It was shown
that disrupting the Wnt/β-catenin pathway by glycogen
synthase-3β (GSK-3β) inhibitors promoted the gener-
ation of CD44lowCD62LhighSca-1highCD122highBcl-2high
self-renewing multipotent CD8+ TSCM cells with prolif-
erative and antitumor capacities that exceeded those of
the TCM and TEM subsets [11, 26, 27]. In addition,
antigen-specific TSCM cells were shown to preferentially
reside in the lymph nodes (LNs) and less so in the spleen
and bone marrow [28].
There are numerous factors that act as modulators regu-
lating the maturation and activation of CD8+ T cells, for ex-
ample, suppressor of cytokine signaling (SOCS) is one of
the key modulators [29]. Moreover, it has been reported
that activation of naive T cells with anti-CD3 and anti-
CD28 antibody-conjugated beads in the presence of low
doses of IL-7 and IL-15 promotes the generation of
CD45RA+CD62L+CCR7+CD95+ TSCM cells [30].
Antigen-specific TSCM
It is well known that antigen-specific T cells are crucial
components for antitumor or antivirus immunity in pa-
tients with hematological malignancies, particularly in
patients after HSCT. It is possible that the number of
antigen-specific TSCM cells may be the determining fac-
tor of immunity. However, there have been few reports
on antigen-specific TSCM cells. Low frequency of these
cells limits detailed characterization. For example, <1 %
of total human T cells are defined as CD8+CD45RA
+CCR7+CD127+CD95+ viral-specific TSCM cells. Human
CMV-specific TSCM cells can be detected at frequencies
similar to those observed in other subsets, with fre-
quency around ∼1/10,000 T cells [31, 32].
Antigen-specific TSCM cells represent a long-lasting
component of the cellular immune response to viruses
and tumor-associated antigens (TAAs). For virus-specific
TSCM cells, research has first focused on human immuno-
deficiency virus type 1 (HIV-1)-specific CD8+ TSCM cells.
It is known that HIV-specific CD8+ T cells can influence
HIV-1 disease progression during untreated HIV-1 infec-
tions, and recent data have shown that HIV-1-specific
CD8+ TSCM cells are detectable in all stages of HIV-1 in-
fection. These cells were found to be increased in number
in patients receiving suppressive antiretroviral therapy
when compared with those untreated patients [33]. It was
found that CD4+ TSCM cells were susceptible to HIV in-
fection; thus, HIV-1 virus may exploit the stem cell char-
acteristics of cellular immune memory T cells and lead to
long-term viral persistence [34]. Similar findings were
demonstrated in a study of human T cell leukemia virus
type 1 (HTLV-1)-infected CD4+ TSCM cells in patients
with adult T cell leukemia (ATL). This report first demon-
strated an association between T cell malignancy and
TSCM cells. TSCM cells from ATL patients were capable of
sustaining themselves in a less proliferative mode, yet they
were able to differentiate into other memory T cell
Table 1 Summary of the expression of functional molecules in

















“+” positive expression, “−” negative expression, TN naive T cell, TSCM stem cell
memory T cell, TCM central memory T cell, TEM effector memory T cell, TTE
terminal effector T cell
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populations during the rapidly propagating phase. These
cells have been identified at the hierarchical apex capable
of reconstituting identical ATL clones [35]. A decrease in
the infection of CD4+ TSCM cells was found to preserve
CD4+ T cell homeostasis and prevents disease progression
despite significant viremia in both HIV-1 and HTLV-1 in-
fections [36].
TSCM cells may play a major role in specific antitumor
response and long-term immune surveillance directed
against tumors [17, 37, 38]. In addition, TSCM cells have
been proposed to be one of the key determinants of im-
mune memory. It may be interesting to monitor the level
of TSCM cells and its significance for immune reconstitu-
tion and prognosis of patients with hematological malig-
nancies before and after therapy, particularly HSCT.
There have been only a few studies on TAA-specific TSCM
cells. Recently, dynamic changes of TSCM cells were longi-
tudinally tracked in patients who underwent haploidenti-
cal HSCT. These studies demonstrated that donor-derived
TSCM cells were highly enriched early after HSCT. TSCM
cells can differentiate directly from naive precursors in-
fused in the grafts. Through T cell receptor (TCR) gene
analysis, TSCM cells have been found to have diversifica-
tion in immune memory after allogeneic HSCT [10]. It
was also demonstrated that the level of TSCM cells may be
used to evaluate immune reconstitution in patients who
received posttransplant cyclophosphamide (pt-Cy) for
GVHD prophylaxis. Similarly, donor-derived TSCM cells
were found to be the most abundant circulating T cell
population in the early days following haploidentical
HSCT and pt-Cy. These donor-derived TSCM cells pre-
ceded the expansion of effector cells. Antigen-specific
TSCM cells generated detectable recall responses; thus, it
has been proposed to explore TSCM cells derived from
donor naive precursor cells in the clinical setting to over-
come immunodeficiency [12]. With the ability to expand
and differentiate into effectors capable of mediating potent
xenogeneic GVHD in immunodeficient mice, these donor
naive precursor-derived TSCM cells were noted to be su-
perior to other memory lymphocytes. Furthermore, gene-
modified TSCM cells were found to be the only T cell sub-
set capable of expanding and mediating GVHD in serial
transplantations [30]. These findings indicate negative as-
pects of TSCM cells for clinical application.
The potential of TSCM cells in immunotherapy for
hematological malignancies
TSCM cells may be a novel and critical therapeutic re-
source because these cells have the potential to serve as
a stable cellular vehicle. Two gene therapy clinical trials
with gene-corrected hematopoietic stem cells provided a
glimpse into this possibility. Long-term in vivo T cell re-
constitution was characterized in these trials. Specific-
ally, the investigators traced the fate of greater than
1700 individual T cell clones in patients who underwent
gene therapy. The studies demonstrated that the TSCM
cells persisted and preserved their precursor potential in
humans for up to 12 years after the infusion of gene-
corrected stem cells [39]. The demonstration of the safe,
functional, and decade-long survival of the engineered
TSCM cells in humans sets the stage for their clinical ap-
plication. Since TSCM cells were shown to be capable of
reconstituting the full repertoire of memory and effector
T cells after HSCT, it is particularly attractive to use
them for adoptive immunotherapies. TSCM cells might
overcome current limitations, such as inefficient T cell
engraftment, poor persistence, and inability to mediate
prolonged immune attacks [10–12, 40].
Even though potent antitumor activity of TSCM cells
was demonstrated in preclinical animal tumor models
[26, 27], it is currently not feasible to treat patients with
naturally occurring TSCM cells because it is a scarce and
Fig. 1 Schematic model for T cell differentiation. Upon activation, naive T cells differentiate into various memory and effector cells. Self-renewal
capacity, multipotency, and proliferation potential decrease upon differentiation. The expression of CD45R0, CCR7, CD28, and CD95 markers
changes during T cell differentiation from TN to TTE. The minimum set of canonical markers can be used to identify the five major subsets of T
cells. TN naive T cell, TSCM stem cell memory T cell, TCM central memory T cell, TEM effector memory T cell, TTE terminal effector T cell
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small proportion of circulating lymphocytes. Therefore,
strategies that can generate, expand, and enable the re-
direction of TSCM cells against cancer cells need to be
defined. Cieri and colleagues have recently described
that a large number of TSCM cells were generated by
priming T cells with low doses of IL-7 and IL-15. It is
therefore possible to generate, expand, and genetically
engineer TSCM cells in vitro from naive precursors. Fur-
thermore, the in vitro-generated TSCM cells displayed
enhanced proliferative capacity upon adoptive transfer
into immunodeficient mice, a finding consistent with
those using naturally occurring TSCM cells [11, 30]. TSCM
cells were also expanded from naive precursors by inhi-
biting Akt signaling during ex vivo priming and expan-
sion. The Akt-inhibited minor histocompatibility antigen
(MiHA)-specific CD8+ T cells had superior expansion
capacity in vitro and induced superior antitumor activity
in multiple myeloma-bearing immunodeficient mice.
These findings provided a rationale for clinically exploit-
ing ex vivo-generated, Akt-inhibited, MiHA-specific
CD8+ T cells or TAA-specific CD8+ T cells for adoptive
immunotherapy [41, 42]. Schmueck-Henneresse et al.
also described a simplified culture protocol allowing for
fast expansion of virus-specific TSCM cells from a mixed
TN/TSCM pool of peripheral blood lymphocytes. This
may be the basis for novel cell therapeutic options for
life-threatening viral infections [31]. Among the known
memory T cell subpopulations, the TSCM cell subset has
profound implications for the design and development
of effective vaccines as well as T cell-based therapies
[13, 26, 28]. As immunotherapy plays increasingly im-
portant roles in cancer management, further explor-
ation of TSCM cells and their regulation may facilitate
clinical development of humoral (monoclonal anti-
bodies and inhibitors of B cell receptor signaling) and
cellular (CART) immunotherapies [40, 43–47].
Conclusions and future perspectives
TSCM cells have the capacities of self-renewal and
differentiation into various memory/effector subsets.
These cells can lead to superior immune reconstitu-
tion. The identification of human TSCM cells is directly
relevant for evaluating life-long cellular immune sta-
tus, immune reconstitution after allogeneic HSCT, and
design of vaccines and T cell immunotherapy. How-
ever, it remains unclear at this time whether the num-
ber of TSCM cells may be used as a standard
biomarker for immune reconstitution after HSCT. In
addition, the low number of TSCM cells in circulating
lymphocytes is also limiting their application [11].
Strategies for in vitro and in vivo isolation and gener-
ation of highly effective antitumor TSCM cells are
under intensive investigation.
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